The 36-month beta value for DRIO is also noteworthy at 1.39. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for DRIO is 29.75M, and at present, short sellers hold a 10.30% of that float. The average trading volume of DRIO on January 31, 2025 was 555.02K shares.
DRIO) stock’s latest price update
DarioHealth Corp (NASDAQ: DRIO) has seen a decline in its stock price by -1.58 in relation to its previous close of 0.64. However, the company has experienced a -10.17% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-01-30 that NEW YORK–(BUSINESS WIRE)—- $DRIO #GLP1–PESG Releases Report: In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it seems DarioHealth’s multi-condition digital health platform and its accelerating financial trajectory may position it as a sleeper hit in a rapidly growing sector. Breaking Down the Opportunity At the heart of DarioHealth’s success is.
DRIO’s Market Performance
DarioHealth Corp (DRIO) has seen a -10.17% fall in stock performance for the week, with a -19.84% decline in the past month and a -33.69% plunge in the past quarter. The volatility ratio for the week is 10.14%, and the volatility levels for the past 30 days are at 22.24% for DRIO. The simple moving average for the past 20 days is -19.47% for DRIO’s stock, with a -40.08% simple moving average for the past 200 days.
Analysts’ Opinion of DRIO
Many brokerage firms have already submitted their reports for DRIO stocks, with TD Cowen repeating the rating for DRIO by listing it as a “Hold.” The predicted price for DRIO in the upcoming period, according to TD Cowen is $1 based on the research report published on January 29, 2025 of the current year 2025.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see DRIO reach a price target of $8.75. The rating they have provided for DRIO stocks is “Buy” according to the report published on May 13th, 2022.
Cowen gave a rating of “Outperform” to DRIO, setting the target price at $31 in the report published on April 22nd of the previous year.
DRIO Trading at -17.22% from the 50-Day Moving Average
After a stumble in the market that brought DRIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.77% of loss for the given period.
Volatility was left at 22.24%, however, over the last 30 days, the volatility rate increased by 10.14%, as shares sank -19.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.16% lower at present.
During the last 5 trading sessions, DRIO fell by -10.02%, which changed the moving average for the period of 200-days by -44.65% in comparison to the 20-day moving average, which settled at $0.7824. In addition, DarioHealth Corp saw -19.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DRIO starting from Nelson Steven Charles, who purchase 5,000 shares at the price of $0.91 back on Nov 12 ’24. After this action, Nelson Steven Charles now owns 55,000 shares of DarioHealth Corp, valued at $4,546 using the latest closing price.
Nelson Steven Charles, the Chief Commercial Officer of DarioHealth Corp, purchase 5,000 shares at $0.84 during a trade that took place back on Sep 10 ’24, which means that Nelson Steven Charles is holding 45,000 shares at $4,221 based on the most recent closing price.
Stock Fundamentals for DRIO
Current profitability levels for the company are sitting at:
- -2.58 for the present operating margin
- 0.4 for the gross margin
The net margin for DarioHealth Corp stands at -1.5. The total capital return value is set at -0.65. Equity return is now at value -50.90, with -29.75 for asset returns.
Based on DarioHealth Corp (DRIO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.28. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -40.25.
Currently, EBITDA for the company is -54.38 million with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.71. The receivables turnover for the company is 2.75for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.57.
Conclusion
In summary, DarioHealth Corp (DRIO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
